✦ LIBER ✦

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer

✍ Scribed by A. J. Montero; C. M. Diaz-Montero; Y. E. Deutsch; J. Hurley; L. G. Koniaris; T. Rumboldt; S. Yasir; M. Jorda; E. Garret-Mayer; E. Avisar; J. Slingerland; O. Silva; C. Welsh; K. Schuhwerk; P. Seo; M. D. Pegram; S. Glück

Publisher: Springer US
Year: 2011
Tongue: English
Weight: 398 KB
Volume: 132
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-011-1889-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multicenter phase II study of trastuzuma

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

✍ M. Venturini; C. Bighin; S. Monfardini; F. Cappuzzo; N. Olmeo; A. Durando; F. Pu 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 218 KB

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views